Imdelltra access in India: the CDSCO Rule 36 named-patient pathway
How Indian patients with previously treated extensive-stage small cell lung cancer legally obtain Imdelltra (tarlatamab-dlle) from US-source supply when the medicine is not yet registered locally, with 22 to 24 hour inpatient monitoring readiness built into the case plan.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Imdelltra in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Imdelltra (tarlatamab-dlle) is the first DLL3-targeted bispecific T-cell engager approved by the US FDA. Accelerated approval was granted on 16 May 2024 and converted to traditional (full) approval on 19 November 2025 for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. It is administered as an intravenous infusion only. There is no public record of Imdelltra registration in India (CDSCO) as of this review. Reserve Meds coordinates the US-side specialty wholesaler sourcing through Amgen's authorized channels under DSCSA serialization, validated 2 to 8 degree Celsius cold-chain logistics, and the documentation kit your medical oncologist needs to file.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why patients in India need Imdelltra via the named-patient pathway
India's oncology capability is deep. What is missing for ES-SCLC patients post-platinum is a routinely stocked DLL3-targeted bispecific antibody on hospital formularies. Imdelltra may not be registered with CDSCO (we confirm its current CDSCO status for your case at intake); personal importation under Rule 36 is the legal route.
The clinical urgency is acute. ES-SCLC carries a poor prognosis, and the post-platinum setting historically had very few effective options. Before Imdelltra's 2024 approval, second-line ES-SCLC in most jurisdictions defaulted to topotecan, lurbinectedin where approved, or re-challenge with platinum-based chemotherapy. None of these match the response rate or response duration seen in the Imdelltra DeLLphi-301 trial in the platinum-pretreated population. SCLC progresses rapidly after platinum failure, and treatment delays cost meaningful time. Indian oncologists at expert thoracic-oncology centres routinely require US lot-level DSCSA traceability for a launch-phase biologic, which is the operating standard Reserve Meds maintains.
The CDSCO Rule 36 named-patient pathway for Imdelltra
The legal foundation for personal import of an unregistered medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits the import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the DCGI at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported is capped at one hundred average doses per application.
For institutional Compassionate Use of drugs not approved for marketing in India at all, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. This route applies when the drug is approved by a recognised reference authority (FDA, EMA, MHRA, Health Canada, PMDA) for a life-threatening condition. ES-SCLC after platinum failure fits the life-threatening condition framing precisely.
For Imdelltra specifically, the clinical-justification angle is precise. The strongest Form 12A applications consistently document: pathology-confirmed small cell lung cancer with extensive-stage disease; documentation of prior platinum-based chemotherapy with dates and the documented progression on or after that line; current performance status and relevant comorbidities; the rationale for Imdelltra over the available alternatives (topotecan, lurbinectedin where approved, platinum re-challenge); the proposed dosing plan following the FDA-labeled step-up schedule (Cycle 1 Day 1 at 1 mg, Cycle 1 Day 8 and Day 15 at 10 mg, then 10 mg every two weeks in maintenance until progression or unacceptable toxicity); and most critically the planned 22 to 24 hour inpatient monitoring readiness after the Cycle 1 Day 1 dose and the Cycle 1 Day 8 dose, with documentation that the dispensing institution can deliver inpatient observation, CRS readiness, and an ICANS-response plan. The kit composition (1 mg vial, 10 mg vial, and the IV Solution Stabilizer vial) ships together as a single unit; partial-kit sourcing is not viable. CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing, and first-time or complex imports can take longer. We give you a written timeline estimate for your case before you commit.
Where Imdelltra gets dispensed in India
Imdelltra requires a hospital with adult medical-oncology capacity, an infusion suite for the approximately one-hour IV administration, and inpatient or extended-monitoring capability for the 22 to 24 hour observation after the Cycle 1 Day 1 (1 mg) dose and the Cycle 1 Day 8 (10 mg) dose. Subsequent infusions require at least six to eight hours of post-infusion monitoring if prior infusions were tolerated.
For Imdelltra, the 22 to 24 hour inpatient monitoring requirement is the gating institutional capability. We will not coordinate Imdelltra delivery to a patient who is not under the care of a medical oncologist with admitting privileges at a facility capable of inpatient extended monitoring with CRS and ICANS readiness.
Real cost picture for Imdelltra in India
Medicine price: quote on request. You get a written quote for your case before you commit.
India's Union Budget 2026-27 expanded customs-duty exemption on a set of named cancer medicines; the specific HSN code and exemption status of each Imdelltra shipment is confirmed at the documentation stage. GST on most life-saving medicines is 5 percent. The dispensing hospital's infusion fees, the inpatient monitoring stay for the first two doses, premedication (dexamethasone, IV hydration of at least 1 litre of normal saline before and after), and supportive care for any CRS or neurologic events sit on the hospital's side of the ledger. Reserve Meds itemises the US-side procurement, the international cold-chain logistics, and the coordination fee separately on every firm quote.
None of the major Indian private insurers reimburse a Rule 36 personal import of an unregistered oncology biologic as a standard line item. CGHS provides for life-saving and anti-cancer medicines that are not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS), case by case, with stricter constraints on drugs not approved by DCGI. Cash-pay is the operating default. Ayushman Bharat PMJAY does not, in practice, cover most high-cost originator specialty drugs for advanced oncology.
Typical timeline for Imdelltra in India
CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing. We give you a written timeline estimate for your case before you commit. A first-time Imdelltra import at an institution that has not previously stocked a DLL3-targeted BiTE may add two to four weeks for institutional pharmacy onboarding, confirmation of inpatient monitoring capacity, and CRS and ICANS readiness review. Because Imdelltra is dosed every two weeks in maintenance after the Cycle 1 step-up schedule, Reserve Meds quotes patients for an initial sourcing window (typically the first two to three cycles) and re-quotes ongoing access as treatment continues.
What your physician needs to provide
The clinical justification letter is the cornerstone of the Form 12A filing. For Imdelltra, the strongest letters consistently include: pathology-confirmed small cell lung cancer with extensive-stage disease, with the staging documentation and any relevant imaging; documentation of prior platinum-based chemotherapy regimens with dates and the documented progression on or after that line; current performance status (ECOG) and relevant comorbidities including any prior CNS involvement; the rationale for Imdelltra over topotecan, lurbinectedin where approved, or platinum re-challenge; the proposed dosing plan following the FDA-labeled step-up schedule (Cycle 1 Day 1 at 1 mg, Cycle 1 Day 8 and Day 15 at 10 mg, then 10 mg every two weeks); the planned monitoring plan including 22 to 24 hours of post-infusion monitoring after the first two doses with explicit CRS and ICANS readiness language; the premedication plan (intravenous dexamethasone or equivalent before the first two doses, plus IV hydration of at least one litre of normal saline before and after these infusions); and the prescribing oncologist's NMC registration number. The dispensing institution's drug licence, the chain-of-custody plan from the US specialty wholesaler to the Indian hospital pharmacy, and the patient identifier complete the file.
The treating oncologist retains the clinical decision and the Pharmacovigilance Programme of India (PvPI) adverse-event reporting obligation. Reserve Meds includes the PvPI reference in the physician documentation kit; the reporting obligation itself stays with the prescribing physician.
Common questions about Imdelltra in India
Will a private insurer cover Imdelltra?
Each plan handles named-patient imports case by case. None of the major Indian private insurers reimburse a Rule 36 personal import of an unregistered oncology biologic as a standard line item. Some plans have considered case-by-case reimbursement for oncology indications with documented prior-line failure. Reserve Meds provides the itemised documentation that lets the insurer evaluate. Cash-pay is the operating default.
What is the safety profile we should be aware of?
The Imdelltra FDA label carries a boxed warning for cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). In the DeLLphi-301 trial, CRS occurred in approximately 51 percent of patients on the 10 mg dose, with most events being grade 1 or 2 and occurring during Cycle 1. Other common adverse reactions in over 20 percent of patients included fatigue, pyrexia, dysgeusia (taste alteration), decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. Patients should be advised not to drive or operate heavy machinery for 48 hours after each infusion because of the risk of neurologic events.
What is the inpatient monitoring requirement?
Patients must be monitored in an appropriate healthcare setting for 22 to 24 hours after the Cycle 1 Day 1 (1 mg) dose and after the Cycle 1 Day 8 (10 mg) dose. Subsequent infusions require at least six to eight hours of post-infusion monitoring if prior infusions were tolerated. Reserve Meds confirms the receiving facility's capacity to meet this requirement as part of intake clinical review; an oncology centre without inpatient extended-monitoring capability is not an acceptable destination for the first two Imdelltra doses.
Will my MoH-affiliated or government-medical-college oncologist's letter be sufficient?
Yes. Any Registered Medical Practitioner with a valid NMC registration number can support a Form 12A application.
Is there a competitor or alternative?
In the post-platinum ES-SCLC setting, alternatives include topotecan (intravenous or oral), lurbinectedin where approved, and platinum re-challenge for selected patients. None of these are DLL3-targeted; Imdelltra is the only approved DLL3 BiTE. The choice between options is the treating oncologist's clinical decision based on patient-specific factors including prior therapy, performance status, comorbidities, prior CNS involvement, and access. Reserve Meds does not select therapy.
What is the typical course duration?
Treatment continues until disease progression or unacceptable toxicity; there is no fixed-cycle endpoint. Median duration of treatment in the pivotal trial at data cutoff was several months, but responders can remain on therapy substantially longer.
Where Reserve Meds fits in Imdelltra cases
Reserve Meds is a US-based digital health company. We do not replace your oncologist, do not replace CDSCO or the DCGI, and do not replace the dispensing hospital pharmacy or the licensed specialty importer. What we do is orchestrate the US-side specialty wholesaler sourcing through Amgen's authorized network under DSCSA serialization with full pedigree, validated 2 to 8 degree Celsius cold-chain logistics with IATA-compliant validated shippers and continuous temperature monitoring through to handoff, and the documentation kit your oncologist needs for the Form 12A filing. The kit composition (1 mg vial, 10 mg vial, and the IVSS vial) ships together as a single unit; partial-kit sourcing is not viable. Standard NPP coordination applies with particular attention to the dispensing institution's 22 to 24 hour inpatient monitoring capacity and CRS plus ICANS readiness. A single point of contact carries the case from intake through Cycle 1 step-up and into the every-two-week maintenance cadence.
Next step
If an Indian patient with extensive-stage small cell lung cancer has progressed on or after platinum-based chemotherapy and the treating oncologist is considering Imdelltra, start your case at the portal. We will respond within one business day with a documentation kit for your oncologist and a written quote.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.